Biến chứng từ Xạ trị cơ thể chính xác trong điều trị ung thư phổi
Tóm tắt
Xạ trị cơ thể chính xác (SBRT) đã trở thành một phương pháp điều trị tiêu chuẩn cho ung thư phổi không tế bào nhỏ (NSCLC) giai đoạn sớm, không có hạch bạch huyết ở những bệnh nhân không thể phẫu thuật vì lý do y tế hoặc từ chối phẫu thuật cắt bỏ. SBRT có tỷ lệ kiểm soát tại chỗ cao và có hồ sơ độc tính thuận lợi so với các phương pháp phẫu thuật và không phẫu thuật khác. Với tỷ lệ kiểm soát khối u xuất sắc và việc sử dụng SBRT ngày càng tăng, những nỗ lực gần đây đã tập trung vào việc hạn chế độc tính trong khi mở rộng điều trị cho những bệnh nhân ngày càng phức tạp. Chúng tôi xem xét các độc tính từ SBRT cho ung thư phổi, bao gồm đường hô hấp trung tâm, thực quản, mạch máu (ví dụ, động mạch chủ), nhu mô phổi (ví dụ, viêm phổi do xạ trị) và độc tính từ thành ngực, cũng như các bệnh lý thần kinh do bức xạ (ví dụ, đám rối brachial, dây thần kinh lang thang và dây thần kinh thanh quản quay). Chúng tôi tóm tắt các đặc điểm liên quan đến bệnh nhân, khối u, đặc tính liều lượng của những độc tính này, xem xét các hạn chế liều đã được công bố và đề xuất các chiến lược để giảm thiểu các biến chứng này.
Từ khóa
#Xạ trị cơ thể chính xác #ung thư phổi không tế bào nhỏ #độc tính #viêm phổi do xạ trị #thần kinh do bức xạTài liệu tham khảo
Senan, 2012, Stereotactic body radiotherapy: Do central lung tumors still represent a “no-fly zone”?, Onkologie, 35, 406, 10.1159/000341091
Haffty, 1988, Results of radical radiation therapy in clinical stage I, technically operable non-small cell lung cancer, Int. J. Radiat. Oncol. Biol. Phys., 15, 69, 10.1016/0360-3016(88)90348-3
Gauden, 1995, The curative treatment by radiotherapy alone of stage I non-small cell carcinoma of the lung, Chest, 108, 1278, 10.1378/chest.108.5.1278
Fang, 2006, Comparison of outcomes for patients with medically inoperable stage I non-small-cell lung cancer treated with two-dimensional vs. Three-dimensional radiotherapy, Int. J. Radiat. Oncol. Biol. Phys., 66, 108, 10.1016/j.ijrobp.2006.04.015
Rosenzweig, 2005, Results of a phase I dose-escalation study using three-dimensional conformal radiotherapy in the treatment of inoperable nonsmall cell lung carcinoma, Cancer, 103, 2118, 10.1002/cncr.21007
Bradley, 2005, Toxicity and outcome results of rtog 9311: A phase I–II dose-escalation study using three-dimensional conformal radiotherapy in patients with inoperable non-small-cell lung carcinoma, Int. J. Radiat. Oncol. Biol. Phys., 61, 318, 10.1016/j.ijrobp.2004.06.260
Narayan, 2004, Results following treatment to doses of 92.4 or 102.9 gy on a phase I dose escalation study for non-small cell lung cancer, Lung Cancer, 44, 79, 10.1016/j.lungcan.2003.09.015
Barriger, 2012, A dose-volume analysis of radiation pneumonitis in non-small cell lung cancer patients treated with stereotactic body radiation therapy, Int. J. Radiat. Oncol. Biol. Phys., 82, 457, 10.1016/j.ijrobp.2010.08.056
Timmerman, 2003, Extracranial stereotactic radioablation: Results of a phase I study in medically inoperable stage I non-small cell lung cancer, Chest, 124, 1946, 10.1378/chest.124.5.1946
Timmerman, 2006, Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer, J. Clin. Oncol., 24, 4833, 10.1200/JCO.2006.07.5937
Amini, A., Yeh, N., Gaspar, L.E., Kavanagh, B., and Karam, S.D. (2014). Stereotactic body radiation therapy (sbrt) for lung cancer patients previously treated with conventional radiotherapy: A review. Radiat. Oncol., 9.
Zheng, 2014, Survival outcome after stereotactic body radiation therapy and surgery for stage I non-small cell lung cancer: A meta-analysis, Int. J. Radiat. Oncol. Biol. Phys., 90, 603, 10.1016/j.ijrobp.2014.05.055
Crabtree, 2010, Stereotactic body radiation therapy versus surgical resection for stage I non-small cell lung cancer, J. Thorac. Cardiovasc. Surg., 140, 377, 10.1016/j.jtcvs.2009.12.054
Lo, 2010, Stereotactic body radiation therapy: A novel treatment modality, Nat. Rev. Clin. Oncol., 7, 44, 10.1038/nrclinonc.2009.188
Fakiris, 2009, Stereotactic body radiation therapy for early-stage non-small-cell lung carcinoma: Four-year results of a prospective phase ii study, Int. J. Radiat. Oncol. Biol. Phys., 75, 677, 10.1016/j.ijrobp.2008.11.042
Song, 2009, Fractionated stereotactic body radiation therapy for medically inoperable stage I lung cancer adjacent to central large bronchus, Lung Cancer, 66, 89, 10.1016/j.lungcan.2008.12.016
Le, 2006, Results of a phase I dose-escalation study using single-fraction stereotactic radiotherapy for lung tumors, J. Thorac. Oncol., 1, 802, 10.1097/01243894-200610000-00008
Kelsey, 2006, Radiation-induced narrowing of the tracheobronchial tree: An in-depth analysis, Lung Cancer, 52, 111, 10.1016/j.lungcan.2005.11.007
Speiser, 1993, Radiation bronchitis and stenosis secondary to high dose rate endobronchial irradiation, Int. J. Radiat. Oncol. Biol. Phys., 25, 589, 10.1016/0360-3016(93)90003-E
Karlsson, 2013, Retrospective cohort study of bronchial doses and radiation-induced atelectasis after stereotactic body radiation therapy of lung tumors located close to the bronchial tree, Int. J. Radiat. Oncol. Biol. Phys., 87, 590, 10.1016/j.ijrobp.2013.06.2055
Rowe, 2012, Stereotactic body radiotherapy for central lung tumors, J. Thorac. Oncol., 7, 1394, 10.1097/JTO.0b013e3182614bf3
Corradetti, 2012, Central-airway necrosis after stereotactic body-radiation therapy, N. Engl. J. Med., 366, 2327, 10.1056/NEJMc1203770
Wu, 2014, Dosimetric predictors of esophageal toxicity after stereotactic body radiotherapy for central lung tumors, Radiother. Oncol., 112, 267, 10.1016/j.radonc.2014.07.001
Onimaru, 2003, Tolerance of organs at risk in small-volume, hypofractionated, image-guided radiotherapy for primary and metastatic lung cancers, Int. J. Radiat. Oncol. Biol. Phys., 56, 126, 10.1016/S0360-3016(03)00095-6
Palma, 2013, Predicting esophagitis after chemoradiation therapy for non-small cell lung cancer: An individual patient data meta-analysis, Int. J. Radiat. Oncol. Biol. Phys., 87, 690, 10.1016/j.ijrobp.2013.07.029
Gomez, 2009, Low rate of thoracic toxicity in palliative paraspinal single-fraction stereotactic body radiation therapy, Radiother. Oncol., 93, 414, 10.1016/j.radonc.2009.10.017
Timmerman, 2008, An overview of hypofractionation and introduction to this issue of seminars in radiation oncology, Semin. Radiat. Oncol., 18, 215, 10.1016/j.semradonc.2008.04.001
Abelson, 2012, Esophageal tolerance to high-dose stereotactic ablative radiotherapy, Dis. Esophagus, 25, 623, 10.1111/j.1442-2050.2011.01295.x
Pequignot, 2000, Predictors of severe esophagitis include use of concurrent chemotherapy, but not the length of irradiated esophagus: A multivariate analysis of patients with lung cancer treated with nonoperative therapy, Int. J. Radiat. Oncol. Biol. Phys., 48, 689, 10.1016/S0360-3016(00)00699-4
Scappaticci, 2005, Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab, J. Surg Oncol., 91, 173, 10.1002/jso.20301
Goodgame, 2008, Tracheo-esophageal fistula with bevacizumab after mediastinal radiation, J. Thorac. Oncol., 3, 1080, 10.1097/JTO.0b013e3181858eba
NCT02319889: Pilot Study of SBRT Plus Chemotherapy for Non-Small Cell Lung Carcinoma, Available online: https://clinicaltrials.gov/ct2/show/NCT02319889.
Evans, 2013, Aortic dose constraints when reirradiating thoracic tumors, Radiother. Oncol., 106, 327, 10.1016/j.radonc.2013.02.002
Shultz, 2014, Vagal and recurrent laryngeal neuropathy following stereotactic ablative radiation therapy in the chest, Pract. Radiat.Oncol., 4, 272, 10.1016/j.prro.2013.08.005
Forquer, 2009, Brachial plexopathy from stereotactic body radiotherapy in early-stage NSCLC: Dose-limiting toxicity in apical tumor sites, Radiother. Oncol., 93, 408, 10.1016/j.radonc.2009.04.018
Ito, M., Niho, S., Nihei, K., Yoh, K., Ohmatsu, H., and Ohe, Y. (2012). Risk factors associated with fatal pulmonary hemorrhage in locally advanced non-small cell lung cancer treated with chemoradiotherapy. BMC Cancer, 12.
Kim, 2010, Risk factors for fatal hemoptysis after concurrent chemoradiation therapy in patients with non-small cell lung carcinoma, Chonnam Med. J., 46, 19, 10.4068/cmj.2010.46.1.19
Reck, 2012, Predicting and managing the risk of pulmonary haemorrhage in patients with nsclc treated with bevacizumab: A consensus report from a panel of experts, Ann. Oncol., 23, 1111, 10.1093/annonc/mdr463
Chi, A., Nguyen, N.P., and Komaki, R. (2014). The potential role of respiratory motion management and image guidance in the reduction of severe toxicities following stereotactic ablative radiation therapy for patients with centrally located early stage non-small cell lung cancer or lung metastases. Front. Oncol., 4.
Milano, 2009, Central thoracic lesions treated with hypofractionated stereotactic body radiotherapy, Radiother. Oncol., 91, 301, 10.1016/j.radonc.2009.03.005
Oshiro, 2010, Stereotactic body radiotherapy for lung tumors at the pulmonary hilum, Strahlenther. Onkol., 186, 274, 10.1007/s00066-010-2072-y
Ohnishi, 2009, Spontaneous pneumothorax after stereotactic radiotherapy for non-small-cell lung cancer, Jpn. J. Radiol., 27, 269, 10.1007/s11604-009-0333-4
Pezner, 1990, Spontaneous pneumothorax in patients irradiated for hodgkin’s disease and other malignant lymphomas, Int. J. Radiat. Oncol. Biol. Phys., 18, 193, 10.1016/0360-3016(90)90284-Q
Stephans, 2009, Comprehensive analysis of pulmonary function test (pft) changes after stereotactic body radiotherapy (sbrt) for stage I lung cancer in medically inoperable patients, J. Thorac. Oncol., 4, 838, 10.1097/JTO.0b013e3181a99ff6
Henderson, 2008, Baseline pulmonary function as a predictor for survival and decline in pulmonary function over time in patients undergoing stereotactic body radiotherapy for the treatment of stage i non-small-cell lung cancer, Int. J. Radiat. Oncol. Biol. Phys., 72, 404, 10.1016/j.ijrobp.2007.12.051
Guckenberger, 2012, Is there a lower limit of pretreatment pulmonary function for safe and effective stereotactic body radiotherapy for early-stage non-small cell lung cancer?, J. Thorac. Oncol., 7, 542, 10.1097/JTO.0b013e31824165d7
Ohashi, 2005, Differences in pulmonary function before vs. 1 year after hypofractionated stereotactic radiotherapy for small peripheral lung tumors, Int. J. Radiat. Oncol. Biol. Phys., 62, 1003, 10.1016/j.ijrobp.2004.12.050
Takeda, 2013, Reassessment of declines in pulmonary function ≥1 year after stereotactic body radiotherapy, Chest, 143, 130, 10.1378/chest.12-0207
Stanic, S., Paulus, R., Timmerman, R.D., Michalski, J., Barriger, R.B., Bezjak, A., Videtic, G.M., and Bradley, J. (2012). No clinically significant changes in pulmonary function following stereotactic body radiation therapy (sbrt) among medically inoperable patients with early stage peripheral non-small cell lung cancer: An analysis of RTOG 0236. Int. J. Radiat. Oncol. Biol. Phys., 84.
Seppenwoolde, 2004, Regional differences in lung radiosensitivity after radiotherapy for non–small-cell lung cancer, Int. J. Radiat. Oncol. Biol. Phys., 60, 748, 10.1016/j.ijrobp.2004.04.037
Tucker, 2010, Impact of toxicity grade and scoring system on the relationship between mean lung dose and risk of radiation pneumonitis in a large cohort of patients with non–small cell lung cancer, Int. J. Radiat. Oncol. Biol. Phys., 77, 691, 10.1016/j.ijrobp.2009.05.055
Nagata, 2005, Clinical outcomes of a phase I/II study of 48 gy of stereotactic body radiotherapy in 4 fractions for primary lung cancer using a stereotactic body frame, Int. J. Radiat. Oncol. Biol. Phys., 63, 1427, 10.1016/j.ijrobp.2005.05.034
Yamashita, H., Nakagawa, K., Nakamura, N., Koyanagi, H., Tago, M., Igaki, H., Shiraishi, K., Sasano, N., and Ohtomo, K. (2007). Exceptionally high incidence of symptomatic grade 2–5 radiation pneumonitis after stereotactic radiation therapy for lung tumors. Radiat. Oncol., 2.
Guckenberger, 2007, Pulmonary injury and tumor response after stereotactic body radiotherapy (sbrt): Results of a serial follow-up ct study, Radiother. Oncol., 85, 435, 10.1016/j.radonc.2007.10.044
Zimmermann, 2006, Stereotactic hypofractionated radiotherapy in stage I (t1-2 n0 m0) non-small-cell lung cancer (nsclc), Acta Oncol., 45, 796, 10.1080/02841860600913210
Guckenberger, 2010, Dose-response relationship for radiation-induced pneumonitis after pulmonary stereotactic body radiotherapy, Radiother. Oncol., 97, 65, 10.1016/j.radonc.2010.04.027
Lo, 2013, Serious complications associated with stereotactic ablative radiotherapy and strategies to mitigate the risk, Clin. Oncol. (R. Coll. Radiol.), 25, 378, 10.1016/j.clon.2013.01.003
Borst, 2009, Radiation pneumonitis in patients treated for malignant pulmonary lesions with hypofractionated radiation therapy, Radiother. Oncol., 91, 307, 10.1016/j.radonc.2009.02.003
Ong, 2010, Treatment of large stage I–II lung tumors using stereotactic body radiotherapy (SBRT): Planning considerations and early toxicity, Radiother. Oncol., 97, 431, 10.1016/j.radonc.2010.10.003
Kyas, 2007, Prediction of radiation-induced changes in the lung after stereotactic body radiation therapy of non-small-cell lung cancer, Int. J. Radiat. Oncol. Biol. Phys., 67, 768, 10.1016/j.ijrobp.2006.08.066
Hope, 2006, Modeling radiation pneumonitis risk with clinical, dosimetric, and spatial parameters, Int. J. Radiat. Oncol. Biol. Phys., 65, 112, 10.1016/j.ijrobp.2005.11.046
Yorke, 2002, Dose-volume factors contributing to the incidence of radiation pneumonitis in non-small-cell lung cancer patients treated with three-dimensional conformal radiation therapy, Int. J. Radiat. Oncol. Biol. Phys., 54, 329, 10.1016/S0360-3016(02)02929-2
Tucker, 1997, Estimation of the spatial distribution of target cells for radiation pneumonitis in mouse lung, Int. J. Radiat. Oncol. Biol. Phys., 38, 1055, 10.1016/S0360-3016(97)00131-4
West, J.B. (2012). Respiratory Physiology: The Essentials, Wolters Kluwer Health/Lippincott Williams & Wilkins.
Matsuo, 2012, Dose-volume metrics associated with radiation pneumonitis after stereotactic body radiation therapy for lung cancer, Int. J. Radiat. Oncol. Biol. Phys., 83, e545, 10.1016/j.ijrobp.2012.01.018
Yamashita, H., Kobayashi-Shibata, S., Terahara, A., Okuma, K., Haga, A., Wakui, R., Ohtomo, K., and Nakagawa, K. (2010). Prescreening based on the presence of ct-scan abnormalities and biomarkers (kl-6 and sp-d) may reduce severe radiation pneumonitis after stereotactic radiotherapy. Radiat. Oncol., 5.
Iwata, 2011, Correlation between the serum kl-6 level and the grade of radiation pneumonitis after stereotactic body radiotherapy for stage i lung cancer or small lung metastasis, Radiother. Oncol., 101, 267, 10.1016/j.radonc.2011.05.031
Kong, 2008, The use of blood biomarkers to predict radiation lung toxicity: A potential strategy to individualize thoracic radiation therapy, Cancer Control., 15, 140, 10.1177/107327480801500206
Hara, 2004, Serum levels of kl-6 for predicting the occurrence of radiation pneumonitis after stereotactic radiotherapy for lung tumors, Chest, 125, 340, 10.1378/chest.125.1.340
Takeda, 2010, Early graphical appearance of radiation pneumonitis correlates with the severity of radiation pneumonitis after stereotactic body radiotherapy (sbrt) in patients with lung tumors, Int. J. Radiat. Oncol. Biol. Phys., 77, 685, 10.1016/j.ijrobp.2009.06.001
Yamaguchi, 2013, Stereotactic body radiotherapy for lung tumors in patients with subclinical interstitial lung disease: The potential risk of extensive radiation pneumonitis, Lung Cancer, 82, 260, 10.1016/j.lungcan.2013.08.024
Palma, 2012, Curative treatment of stage I non-small-cell lung cancer in patients with severe copd: Stereotactic radiotherapy outcomes and systematic review, Int. J. Radiat. Oncol. Biol. Phys., 82, 1149, 10.1016/j.ijrobp.2011.03.005
Kimura, 2006, Ct appearance of radiation injury of the lung and clinical symptoms after stereotactic body radiation therapy (SBRT) for lung cancers: Are patients with pulmonary emphysema also candidates for sbrt for lung cancers?, Int. J. Radiat. Oncol. Biol. Phys., 66, 483, 10.1016/j.ijrobp.2006.05.008
Jin, 2009, Dose-volume thresholds and smoking status for the risk of treatment-related pneumonitis in inoperable non-small cell lung cancer treated with definitive radiotherapy, Radiother. Oncol., 91, 427, 10.1016/j.radonc.2008.09.009
Takeda, 2012, Severe COPD is correlated with mild radiation pneumonitis following stereotactic body radiotherapy, Chest, 141, 858, 10.1378/chest.11-1193
Bjermer, 1993, Tobacco smoke exposure suppresses radiation-induced inflammation in the lung: A study of bronchoalveolar lavage and ultrastructural morphology in the rat, Eur. Respir. J., 6, 1173, 10.1183/09031936.93.06081173
Bhattathiri, 1999, Possible role of plasma GSH in modulating smoking related radiation pneumonitis, Radiother. Oncol., 51, 291
Takeda, 2012, Comparison of clinical, tumour-related and dosimetric factors in grade 0–1, grade 2 and grade 3 radiation pneumonitis after stereotactic body radiotherapy for lung tumours, Br. J. Radiol., 85, 636, 10.1259/bjr/71635286
Stephans, 2009, A comparison of two stereotactic body radiation fractionation schedules for medically inoperable stage I non-small cell lung cancer: The cleveland clinic experience, J. Thorac. Oncol., 4, 976, 10.1097/JTO.0b013e3181adf509
Andolino, 2011, Chest wall toxicity after stereotactic body radiotherapy for malignant lesions of the lung and liver, Int. J. Radiat. Oncol. Biol. Phys., 80, 692, 10.1016/j.ijrobp.2010.03.020
Stephans, 2012, Prediction of chest wall toxicity from lung stereotactic body radiotherapy (SBRT), Int. J. Radiat. Oncol. Biol. Phys., 82, 974, 10.1016/j.ijrobp.2010.12.002
Welsh, 2011, Obesity increases the risk of chest wall pain from thoracic stereotactic body radiation therapy, Int. J. Radiat. Oncol. Biol. Phys., 81, 91, 10.1016/j.ijrobp.2010.04.022
Voroney, 2009, Chest wall pain and rib fracture after stereotactic radiotherapy for peripheral non-small cell lung cancer, J. Thorac. Oncol., 4, 1035, 10.1097/JTO.0b013e3181ae2962
Mutter, 2012, Dose-volume parameters predict for the development of chest wall pain after stereotactic body radiation for lung cancer, Int. J. Radiat. Oncol. Biol. Phys., 82, 1783, 10.1016/j.ijrobp.2011.03.053
Fajardo, L.F., Berthrong, M., and Anderson, R.E. (2001). Radiation Pathology, Oxford University Press.
Bongers, 2011, Incidence and risk factors for chest wall toxicity after risk-adapted stereotactic radiotherapy for early-stage lung cancer, J. Thorac. Oncol., 6, 2052, 10.1097/JTO.0b013e3182307e74
Creach, 2012, Dosimetric predictors of chest wall pain after lung stereotactic body radiotherapy, Radiother. Oncol., 104, 23, 10.1016/j.radonc.2012.01.014
Pettersson, 2009, Radiation-induced rib fractures after hypofractionated stereotactic body radiation therapy of non-small cell lung cancer: A dose- and volume-response analysis, Radiother. Oncol., 91, 360, 10.1016/j.radonc.2009.03.022
Dunlap, 2010, Chest wall volume receiving >30 gy predicts risk of severe pain and/or rib fracture after lung stereotactic body radiotherapy, Int. J. Radiat. Oncol. Biol. Phys., 76, 796, 10.1016/j.ijrobp.2009.02.027
Li, 2014, Stereotactic ablative radiotherapy (SABR) using 70 gy in 10 fractions for non-small cell lung cancer: Exploration of clinical indications, Radiother. Oncol., 112, 256, 10.1016/j.radonc.2014.07.010
Radiation Therapy Oncology Group RTOG 0813: Seamless Phase I/II Study of Stereotactic Lung Radiotherapy (SBRT) for Early Stage, Centrally Located, Non-Small Cell Lung Cancer (NSCLC) in Medically Inoperable Patients. Available online: http://www.rtog.org/ClinicalTrials/ProtocolTable/StudyDetails.aspx?study=0813.
Hoppe, 2008, Acute skin toxicity following stereotactic body radiation therapy for stage i non-small-cell lung cancer: Who’s at risk?, Int. J. Radiat. Oncol. Biol. Phys., 72, 1283, 10.1016/j.ijrobp.2008.08.036
Schierle, 2004, Radiation-induced brachial plexopathy: Review. Complication without a cure, J. Reconstr. Microsurg., 20, 149, 10.1055/s-2004-820771
Ferrante, 2004, Brachial plexopathies: Classification, causes, and consequences, Muscle Nerve, 30, 547, 10.1002/mus.20131
Amini, 2012, Dose constraints to prevent radiation-induced brachial plexopathy in patients treated for lung cancer, Int. J. Radiat. Oncol. Biol. Phys., 82, e391, 10.1016/j.ijrobp.2011.06.1961
Kori, 1981, Brachial plexus lesions in patients with cancer: 100 cases, Neurology, 31, 45, 10.1212/WNL.31.1.45
Chang, 2014, Stereotactic ablative radiation therapy for centrally located early stage or isolated parenchymal recurrences of non-small cell lung cancer: How to fly in a “no fly zone”, Int. J. Radiat. Oncol. Biol. Phys., 88, 1120, 10.1016/j.ijrobp.2014.01.022
Lo, 2009, In regard to Hoppe et al. (Int. J Radiat. Oncol. Biol. Phys. 2008;72:1283–1286), Int. J. Radiat. Oncol. Biol. Phys., 74, 977, 10.1016/j.ijrobp.2009.02.046
Wang, 2011, Lung tumor reproducibility with active breath control (ABC) in image-guided radiotherapy based on cone-beam computed tomography with two registration methods, Radiother. Oncol., 99, 148, 10.1016/j.radonc.2011.05.020
Guckenberger, 2011, A novel respiratory motion compensation strategy combining gated beam delivery and mean target position concept—A compromise between small safety margins and long duty cycles, Radiother. Oncol., 98, 317, 10.1016/j.radonc.2011.01.008
Taremi, 2012, Stereotactic body radiotherapy for medically inoperable lung cancer: Prospective, single-center study of 108 consecutive patients, Int. J. Radiat. Oncol. Biol. Phys., 82, 967, 10.1016/j.ijrobp.2010.12.039
Onishi, 2004, Stereotactic hypofractionated high-dose irradiation for stage I nonsmall cell lung carcinoma: Clinical outcomes in 245 subjects in a japanese multiinstitutional study, Cancer, 101, 1623, 10.1002/cncr.20539
Chang, 2008, Stereotactic body radiation therapy in centrally and superiorly located stage I or isolated recurrent non-small-cell lung cancer, Int. J. Radiat. Oncol. Biol. Phys., 72, 967, 10.1016/j.ijrobp.2008.08.001
Nuyttens, 2012, Outcome of four-dimensional stereotactic radiotherapy for centrally located lung tumors, Radiother. Oncol., 102, 383, 10.1016/j.radonc.2011.12.023
Lagerwaard, 2008, Outcomes of risk-adapted fractionated stereotactic radiotherapy for stage I non-small-cell lung cancer, Int. J. Radiat. Oncol. Biol. Phys., 70, 685, 10.1016/j.ijrobp.2007.10.053
Onishi, 2007, Hypofractionated stereotactic radiotherapy (hypofxsrt) for stage I non-small cell lung cancer: Updated results of 257 patients in a japanese multi-institutional study, J. Thorac. Oncol., 2, S94, 10.1097/JTO.0b013e318074de34
Uematsu, 2001, Computed tomography-guided frameless stereotactic radiotherapy for stage I non-small cell lung cancer: A 5-year experience, Int. J. Radiat. Oncol. Biol. Phys., 51, 666, 10.1016/S0360-3016(01)01703-5
Senan, 2007, Stereotactic radiotherapy for centrally located early-stage lung tumors, J. Clin. Oncol., 25, 464, 10.1200/JCO.2006.09.8178
Olsen, 2011, Dose-response for stereotactic body radiotherapy in early-stage non-small-cell lung cancer, Int. J. Radiat. Oncol. Biol. Phys., 81, e299, 10.1016/j.ijrobp.2011.01.038
Haasbeek, 2011, Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer, J. Thorac. Oncol., 6, 2036, 10.1097/JTO.0b013e31822e71d8
Guckenberger, 2009, Dose-response relationship for image-guided stereotactic body radiotherapy of pulmonary tumors: Relevance of 4d dose calculation, Int. J. Radiat. Oncol. Biol. Phys., 74, 47, 10.1016/j.ijrobp.2008.06.1939
Radiation Therapy Oncology Group RTOG 0915: A Randomized Phase ii Study Comparing 2 Stereotactic Body Radiation Therapy (SBRT) Schedules for Medically Inoperable Patients with Stage I Peripheral Non-Small Cell Lung Cancer. Available online: http://www.rtog.org/ClinicalTrials/ProtocolTable/StudyDetails.aspx?study=0915.
Radiation Therapy Oncology Group RTOG 0236: A Phase II Trial of Stereotactic Body Radiation Therapy (SBRT) in the Treatment of Patients with Medically Inoperable Stage I/II Non-Small Cell Lung Cancer. Available online: http://www.rtog.org/ClinicalTrials/ProtocolTable/StudyDetails.aspx?study=0236.
Nagata, 2011, Stereotactic radiotherapy of primary lung cancer and other targets: Results of consultant meeting of the international atomic energy agency, Int. J. Radiat. Oncol. Biol. Phys., 79, 660, 10.1016/j.ijrobp.2010.10.004
Verbakel, 2009, Rapid delivery of stereotactic radiotherapy for peripheral lung tumors using volumetric intensity-modulated arcs, Radiother. Oncol., 93, 122, 10.1016/j.radonc.2009.05.020
Yang, 2010, Red shell: Defining a high-risk zone of normal tissue damage in stereotactic body radiation therapy, Int. J. Radiat. Oncol. Biol. Phys., 77, 903, 10.1016/j.ijrobp.2009.12.069
Dong, 2013, 4pi noncoplanar stereotactic body radiation therapy for centrally located or larger lung tumors, Int. J. Radiat. Oncol. Biol. Phys., 86, 407, 10.1016/j.ijrobp.2013.02.002
Prevost, 2008, Four-dimensional stereotactic radiotherapy for early stage non-small cell lung cancer: A comparative planning study, Technol. Cancer Res. Treat., 7, 27, 10.1177/153303460800700103
Chi, 2013, Critical structure sparing in stereotactic ablative radiotherapy for central lung lesions: Helical tomotherapy vs. Volumetric modulated arc therapy, PLoS ONE, 8, e59729, 10.1371/journal.pone.0059729
Prendergast, B.M., Dobelbower, M.C., Bonner, J.A., Popple, R.A., Baden, C.J., Minnich, D.J., Cerfolio, R.J., Spencer, S.A., and Fiveash, J.B. (2013). Stereotactic body radiation therapy (SBRT) for lung malignancies: Preliminary toxicity results using a flattening filter-free linear accelerator operating at 2400 monitor units per minute. Radiat. Oncol., 8.
Kragl, 2011, Flattening filter free beams in sbrt and imrt: Dosimetric assessment of peripheral doses, Z. Med. Phys., 21, 91, 10.1016/j.zemedi.2010.07.003